Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has announced the retirement of Richard C. Williams, effective April 15, 2022. Williams has served nearly eight years, providing strategic leadership and valuable insights to the company. CEO Dr. Dennis J. Carlo expressed gratitude for Williams' contributions. Adamis focuses on developing biopharmaceuticals in various therapeutic areas, including allergy and opioid overdose, with FDA-approved products like SYMJEPI® for allergic reactions and ZIMHI™ for opioid overdose treatment. Tempol is also under development for COVID-19.
- Leadership transition with Richard C. Williams retiring after nearly 8 years, indicating stable management changes.
- Ongoing development of Tempol for COVID-19, suggesting potential market expansion.
- Transition of leadership could introduce uncertainty during a critical development period.
- No clear successor announced, raising concerns about continuity in strategic direction.
SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022.
“Dick has provided almost eight years of strategic leadership and committed service to Adamis and has provided valuable insight and counsel to the board as well as our staff. He has been an exemplary leader through the challenges the company has faced and has been fair and unwavering in his support for Adamis,” said Adamis’ CEO and President, Dr. Dennis J. Carlo. “We admire Dick for his work ethic and wish him all the best in his retirement.”
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company’s SYMJEPI® (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company’s ZIMHI™ (naloxone) Injection product is approved for the treatment of opioid overdose. Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway. For additional information about Adamis Pharmaceuticals, please visit www.adamispharmaceuticals.com and follow us on Twitter and LinkedIn.
Contact
Adamis Investor Relations
Robert Uhl
Managing Director
ICR Westwicke
619.228.5886
robert.uhl@westwicke.com
FAQ
When is Richard C. Williams retiring from Adamis Pharmaceuticals?
What is the focus of Adamis Pharmaceuticals?
What products does Adamis Pharmaceuticals offer?
Is Tempol being developed for COVID-19 by Adamis Pharmaceuticals?
